Therapeutic area intelligence for Anticholinergic with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

Edenbridge Pharmaceuticals →

Assets

FDA →

Recent signals(1)

RegulatoryJuly 4, 2026

FDA Grants Approval for Atropine Sulfate ANDA219013 by Edenbridge Pharmaceuticals

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 219013 for Atropine Sulfate submitted by Edenbridge Pharmaceuticals.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.